Psoriatic Arthritis: key endpoint results by drug
The key endpoints of Psoriatic Arthritis trials, with each approved or late-stage drug's result from its own trial: the lead dose against placebo (or the trial's active comparator), the week, and the arm size. These are the same rows as the drug comparison, for every drug at once. To set chosen drugs side by side, with every shared endpoint, use the comparison. The drug list and pipeline are on the Psoriatic Arthritis page.
ACR20
| Drug | Result | Control | Difference | Dose · week · n | Trial |
|---|---|---|---|---|---|
| Abatacept | 39.4% | 22.3% | +17.1 | wk 24 · n 213 | NCT01860976 Phase 3, primary |
| apremilast | 38.1% | 19% | +19.1 | 30 mg · wk 16 · n 168 | NCT01172938 Phase 3, primary |
| bimekizumab | 62.2% | 23.8% | +38.4 | 160 mg Q4W · wk 16 · n 431 | NCT03895203 Phase 3, secondary |
| brodalumab | 41.8% | 24.7% | +17.1 | 210 mg · wk 16 · n 146 | NCT02024646 Phase 3, primary |
| certolizumab pegol | 51.9% | 24.3% | +27.6 | 400 mg Q4W · wk 12 · n 135 | NCT01087788 Phase 3, primary |
| deucravacitinib | 52.9% | 31.8% | +21.1 | 6 mg · wk 16 · n 70 | NCT03881059 Phase 2, primary |
| etanercept | 60.9% | 50.7% (Methotrexate) | — | wk 24 · n 284 | NCT02376790 Phase 3, primary |
| golimumab | 45.2% | 8.8% | +36.4 | 100 mg · wk 14 · n 146 | NCT00265096 Phase 3, primary |
| guselkumab | 52% | 22.2% | +29.8 | 100 mg q8w · wk 24 · n 127 | NCT03162796 Phase 3, primary |
| infliximab | 86.3% | 66.7% (Methotrexate) | — | wk 16 · n 51 | NCT00367237 Phase 3, primary |
| ixekizumab | 53.3% | 19.5% | +33.8 | 80 mg Q4W · wk 24 · n 122 | NCT02349295 Phase 3, primary |
| netakimab | 82%a | 9% | +73 | wk 24 | NCT03598751 Phase 3, primary |
| risankizumab | 61.9% | 35.7% | +26.2 | 150 mg weeks 0, 4, and 16 · wk 16 · n 42 | NCT02719171 Phase 2, primary |
| secukinumab | 59.5% | 27.4% | +32.1 | 150 mg without load · wk 16 · n 222 | NCT02404350 Phase 3, primary |
| tildrakizumab | 0.8% | 0.5% | +0.3 | I · wk 24 · n 78 | NCT02980692 Phase 2, primary |
| tofacitinib | 50.5% | 33.3% | +17.1 | 5 mg twice daily · wk 12 · n 107 | NCT01877668 Phase 3, primary |
| upadacitinib | 70.6% | 36.2% | +34.4 | 15 mg · wk 12 · n 429 | NCT03104400 Phase 3, primary |
| ustekinumab | 49.5% | 22.8% | +26.7 | 90 mg · wk 24 · n 204 | NCT01009086 Phase 3, primary |
| zasocitinib | 35.2% | 29.2% | +6 | wk 12 · n 71 | NCT05153148 Phase 2, primary |
Drugs checked with no result here: 27 not reported, 2 not posted, 4 trial running.
ACR50
| Drug | Result | Control | Difference | Dose · week · n | Trial |
|---|---|---|---|---|---|
| apremilast | 16.1% | 6% | +10.1 | 30 mg · wk 16 · n 168 | NCT01172938 Phase 3, secondary |
| bimekizumab | 43.9% | 10% | +33.9 | 160 mg Q4W · wk 16 · n 431 | NCT03895203 Phase 3, primary |
| deucravacitinib | 24.3% | 10.6% | +13.7 | 6 mg · wk 16 · n 70 | NCT03881059 Phase 2, secondary |
| etanercept | 40.4% | 16.9% (Methotrexate) | — | wk 12 · n 284 | NCT02376790 Phase 3, secondary |
| golimumab | 43.6% | 6.3% | +37.3 | wk 14 · n 241 | NCT02181673 Phase 3, secondary |
| guselkumab | 20.5% | 10.3% | +10.2 | 100 mg q8w · wk 12 · n 127 | NCT03162796 Phase 3, secondary |
| ixekizumab | 35.2% | 5.1% | +30.1 | 80 mg Q4W · wk 24 · n 122 | NCT02349295 Phase 3, secondary |
| risankizumab | 23.8% | 11.9% | +11.9 | 150 mg weeks 0, 4, and 16 · wk 16 · n 42 | NCT02719171 Phase 2, secondary |
| secukinumab | 31.4% | 6.3% | +25 | 6 mg/kg - 3 mg/kg i.v. · wk 16 · n 191 | NCT04209205 Phase 3, primary |
| tofacitinib | 28.0% | 9.5% | +18.5 | 5 mg twice daily · wk 13 · n 107 | NCT01877668 Phase 3, secondary |
| upadacitinib | 37.5% | 13.2% | +24.3 | 15 mg · wk 12 · n 429 | NCT03104400 Phase 3, secondary |
| ustekinumab | 27.9% | 8.7% | +19.2 | 90 mg · wk 24 · n 204 | NCT01009086 Phase 3, secondary |
| zasocitinib | 15.5% | 9.7% | +5.8 | wk 12 · n 71 | NCT05153148 Phase 2, secondary |
Drugs checked with no result here: 29 not reported, 6 not posted, 4 trial running.
PASI 75
| Drug | Result | Control | Difference | Dose · week · n | Trial |
|---|---|---|---|---|---|
| apremilast | 25.6% | 11.2% | +14.4 | 30 mg · wk 24 · n 90 | NCT01212770 Phase 3, secondary |
| bimekizumab | 68.8% | 10% | +58.8 | 160 mg · wk 12 · n 16 | NCT02969525 Phase 2, secondary |
| certolizumab pegol | 60.5% | 15.1% | +45.4 | 400 mg Q4W · wk 24 · n 76 | NCT01087788 Phase 3, secondary |
| deucravacitinib | 42.4% | 20.4% | +22 | 6 mg · wk 16 · n 59 | NCT03881059 Phase 2, secondary |
| golimumab | 58.3% | 2.5% | +55.8 | 100 mg · wk 14 · n 108 | NCT00265096 Phase 3, secondary |
| guselkumab | 75.6% | 14.1% | +61.5 | 100 mg q8w · wk 24 · n 82 | NCT03162796 Phase 3, secondary |
| ixekizumab | 57.4% | 10.4% | +47 | 80 mg Q4W · wk 12 · n 68 | NCT02349295 Phase 3, secondary |
| secukinumab | 48.3% | 16.3% | +32 | 150 mg s.c. · wk 24 · n 58 | NCT01752634 Phase 3, secondary |
| tofacitinib | 42.7% | 14.6% | +28.1 | 5 mg twice daily · wk 13 · n 82 | NCT01877668 Phase 3, secondary |
| upadacitinib | 62.6% | 21.3% | +41.3 | 15 mg · wk 16 · n 214 | NCT03104400 Phase 3, secondary |
| ustekinumab | 62.4% | 11% | +51.4 | 90 mg · wk 24 · n 149 | NCT01009086 Phase 3, secondary |
| zasocitinib | 25.6% | 15.4% | +10.2 | wk 12 · n 39 | NCT05153148 Phase 2, secondary |
Drugs checked with no result here: 28 not reported, 8 not posted, 4 trial running.
Minimal disease activity
| Drug | Result | Control | Difference | Dose · week · n | Trial |
|---|---|---|---|---|---|
| adalimumab | 41.5% | 13.1% (MTX) | — | wk 16 · n 123 | NCT02814175 Phase 4, primary |
| apremilast | 33.9% | 16% | +17.9 | 30 mg · wk 16 · n 203 | NCT03747939 Phase 4, primary |
| bimekizumab | 45% | 13.2% | +31.8 | 160 mg Q4W · wk 16 · n 431 | NCT03895203 Phase 3, secondary |
| deucravacitinib | 22.9% | 7.6% | +15.3 | 6 mg · wk 16 · n 70 | NCT03881059 Phase 2, secondary |
| etanercept | 35.9% | 22.9% (Methotrexate) | — | wk 24 · n 284 | NCT02376790 Phase 3, secondary |
| golimumab | 55.8% | 58.5% (Methotrexate) | — | wk 24 · n 43 | NCT04108468 Phase 3, secondary |
| guselkumab | 22.8% | 11.1% | +11.7 | 100 mg q8w · wk 24 · n 127 | NCT03162796 Phase 3, secondary |
| ixekizumab | 27.9% | 3.4% | +24.5 | 80 mg Q4W · wk 24 · n 122 | NCT02349295 Phase 3, secondary |
| secukinumab | 22.4% | 5.3% | +17.2 | 6 mg/kg - 3 mg/kg i.v. · wk 16 · n 191 | NCT04209205 Phase 3, secondary |
| upadacitinib | 36.6% | 12.3% | +24.3 | 15 mg · wk 24 · n 429 | NCT03104400 Phase 3, secondary |
| ustekinumab | 22.2% | 35.7% (Secukinumab) | — | wk 28 · n 63 | NCT04632927 Phase 3, secondary |
| zasocitinib | 18.3% | 12.5% | +5.8 | wk 12 · n 71 | NCT05153148 Phase 2, secondary |
Drugs checked with no result here: 30 not reported, 6 not posted, 4 trial running.
HAQ-DI, change
| Drug | Result | Control | Difference | Dose · week · n | Trial |
|---|---|---|---|---|---|
| adalimumab | -0.5 | -0.3 (MTX) | — | wk 16 · n 116 | NCT02814175 Phase 4, secondary |
| apremilast | -0.3 | -0.1 | −0.2 | 30 mg · wk 24 · n 161 | NCT01172938 Phase 3, secondary |
| bimekizumab | -0.3 | -0.1 | −0.2 | 160 mg Q4W · wk 16 · n 431 | NCT03895203 Phase 3, secondary |
| certolizumab pegol | -0.5 | -0.2 | −0.3 | 400 mg Q4W · wk 24 · n 135 | NCT01087788 Phase 3, secondary |
| deucravacitinib | -0.4 | -0.1 | −0.3 | 6 mg · wk 16 · n 70 | NCT03881059 Phase 2, secondary |
| etanercept | -0.4 | -0.4 (Methotrexate) | — | wk 24 · n 284 | NCT02376790 Phase 3, secondary |
| golimumab | 0.4 | 0 | +0.4 | 100 mg · wk 24 · n 146 | NCT00265096 Phase 3, secondary |
| guselkumab | -0.3 | -0.1 | −0.2 | 100 mg q8w · wk 24 · n 127 | NCT03162796 Phase 3, secondary |
| ixekizumab | -0.6 | -0.2 | −0.4 | 80 mg Q4W · wk 24 · n 122 | NCT02349295 Phase 3, secondary |
| risankizumab | -0.2 | -0.1 | −0.1 | 150 mg weeks 0, 4, and 16 · wk 16 · n 40 | NCT02719171 Phase 2, secondary |
| secukinumab | -0.5 | -0.3 | −0.2 | 150 mg s.c. · wk 24 · n 95 | NCT01752634 Phase 3, secondary |
| tofacitinib | -0.3 | -0.2 | −0.2 | 5 mg twice daily · wk 12 · n 107 | NCT01877668 Phase 3, primary |
| upadacitinib | -0.4 | -0.1 | −0.3 | 15 mg · wk 12 · n 404 | NCT03104400 Phase 3, secondary |
| ustekinumab | -0.4 | -0.1 | −0.3 | 90 mg · wk 24 · n 204 | NCT01009086 Phase 3, secondary |
| zasocitinib | -0.3 | -0.2 | −0.1 | wk 12 · n 66 | NCT05153148 Phase 2, secondary |
Drugs checked with no result here: 28 not reported, 5 not posted, 4 trial running.
- a From a reviewed publication or company release; CT.gov has no posted result for this endpoint.
- Each cell is from that drug's own trial. Trials differ in population, design and timepoint; this is not a head-to-head comparison.
- Rows are in drug-name order, not ranked. Difference is the lead arm minus placebo, in the endpoint's unit. 52 approved or late-stage drugs with a featured trial in Psoriatic Arthritis were checked; results come from ClinicalTrials.gov posted results unless marked. Updated 2026-11-20. How results are chosen: methodology.